0001816590-26-000042
SEC filingNet income swung to $91.2M on a non-cash fair value gain, masking deeper operating losses as Phase 3 trial costs declined.
Operating loss for Q1 2026 was $42.9 million, a 13.5% improvement from $49.6 million in Q1 2025. The reduction was primarily driven by lower research and development expenses as the Phase 3 program progresses, partially offset by an increase in facilities and other expenses due to higher external consulting fees and contractors. As a clinical-stage biotechnology company with no approved products or revenue, we expect operating losses to continue as we advance our pipeline.
Net income was $91.2 million in Q1 2026, compared to a net loss of $17.9 million in Q1 2025. The swing was primarily due to a non-cash fair value gain on warrant liabilities, which is not indicative of ongoing operational performance. Excluding this gain, the underlying operating loss reflects our continued investment in clinical development and corporate infrastructure.
Net cash used in operating activities was $47.9 million in Q1 2026, compared to $45.7 million in Q1 2025. The increase reflects higher working capital requirements. We believe our existing cash and cash equivalents will be sufficient to fund operating expenses and capital expenditure requirements into 2028. We have incurred significant operating losses since formation and expect to continue incurring costs associated with operating as a public company, including legal, accounting, and investor relations expenses.
We are focused on completing the Phase 3 program for our lead candidate, COMP360, and preparing for a rolling NDA submission. Product candidates in later stages of development generally have higher costs due to larger and longer trials and related manufacturing expenses. We also face risks related to FDA approval, DEA rescheduling of psilocybin, and reliance on third-party manufacturers.
Management expects operating losses to continue increasing as the company completes the Phase 3 program, prepares the rolling NDA submission, and initiates commercial readiness activities. Key risks include the inherent uncertainty of FDA approval, the need for DEA rescheduling of psilocybin from Schedule I, potential delays in regulatory review, and the company's history of operating losses with no approved products or revenue to date. The company also faces risks related to reliance on third-party manufacturers, clinical trial enrollment, and the evolving regulatory landscape for psychedelic therapies.